MM20-03

Main Content

Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma.

Study #: MM20-03

Study Status: Published

Presentation(s)

2022, Tandem (Oral)

Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma.

Citation

Bumma N, Dhakal B, Fraser R, Estrada-Merly N, Anderson K, Freytes CO, Hildebrandt GC, Holmberg L, Krem MM, Lee C, Lekakis L, Lazarus HM, Mian H, Murthy HS, Nathan S, Nishihori T, Parrondo R, Patel SS, Solh M, Strouse C, Vesole DH, Kumar S, Qazilbash MH, Shah N, D'Souza A, Sidana S.

Cancer. 2023, Jul 15: 129(14): 129(14):2179-2191. doi: 10.1002/cncr.34778. Epub 2023, Apr 06. PMCID:PMC10516285.

PubMed

PMID: 37021929

Abstract